
A Digital Tool for Cholesterol Management
Primary Care / Family Medicine, Cardiology (Heart & Vascular), Endocrinology & Diabetes, Nephrology & Urology (Kidneys & Urinary)
2020-12-01 – 2024-01-01

Cardiovascular disease is widespread across Canada. It is the leading cause of death for women, and the second leading cause of death for all Canadians. Dyslipidemia can be modified with effective, safe, and inexpensive treatment using cholesterol-lowering medications, such as statins. Unfortunately, only about 25% to 66% of individuals who would benefit from statins, or other management strategies, are currently benefiting from them.1,2 PLP Medical Directors, Drs. Sonia Butalia, Katrina Nicholson, and Oliver David collaborated extensively with patient partners, family physicians, specialists, and pharmacists to co-create a dyslipidemia clinical decision support tool for individuals and physicians. By visiting the site and reading through the material, individuals can learn about dyslipidemia, statin indicated conditions, use a health heart calculator (Framingham Risk Score), and explore treatment options. Physicians can leverage the physician guide to facilitate evidence-based cholesterol management. This work was funded by Diabetes Canada, and PLP provided in-kind HCD and technical development expertise.
The tool was implemented in November 2023 (https://cholesterol-tool.ucalgary.ca/ ). In collaboration with AHS and Alberta Precision Laboratories, the online clinical decision support tool is included with every lipid profile result, appearing in NetCare, electronic medical records, and other clinical systems. It is also publicly available (https://cholesterol-tool.ucalgary.ca/ ). Health Quality Alberta has integrated it into their panel reports as well.
This year, the platform has continued to captivate, amassing over 11,000 active users from Canada, the United States, the United Kingdom, France, Mexico, India, and China and more than 12,000 direct traffic sessions and 22,000 user engagement sessions.

To further enhance its impact, a series of provincial and national presentations were conducted, aimed at promoting the importance and raising awareness of the shared decision-making process in cholesterol management. Feedback on the tool and platform has been overwhelmingly positive, with recognition coming from across the province, as well as on national and international levels. In acknowledgement of her leadership in this work, Dr. Sonia Butalia was honored as the inaugural recipient of the Dr. Norm Campbell Cardiovascular Disease Prevention Award for her role in developing the “Let’s Talk Cholesterol” tool.
Cardiovascular disease is widespread across Canada. It is the leading cause of death for women, and the second leading cause of death of all Canadians. Dyslipidemia can be modified with effective, safe, and inexpensive treatment using cholesterol-lowering medications, such as statins. Unfortunately, only about 25% to 66% of individuals who would benefit from statins, or other management strategies, are currently benefiting from them.1,2
PLP Medical Directors, Drs. Sonia Butalia, Katrina Nicholson and Oliver David collaborated extensively with patient partners, family physicians, specialists, and pharmacists to co-create a dyslipidemia clinical decision support tool for individuals and physicians. By visiting the site and reading through the material, individuals can learn about dyslipidemia, statin indicated conditions, use a health heart calculator (Framingham Risk Score), and explore treatment options. Physicians can leverage the physician guide to facilitate evidence-based cholesterol management. This work was funded by Diabetes Canada, and PLP provided in-kind HCD and technical development expertise.
The tool was implemented in November 2023 (https://cholesterol-tool.ucalgary.ca/). In collaboration with AHS and Alberta Precision Laboratories, the online clinical decision support tool is included with every lipid profile result, appearing in NetCare, electronic medical records, and other clinical systems. It is also publicly available and has been integrated into Health Quality Alberta panel reports.
Over this past year, the project focused on enhancing the impact of the dyslipidemia clinical decision support tool across the province. Periodic reviews of analytics were conducted to monitor the tool’s effectiveness and patterns of user engagement. These analyses, together with user feedback, identified emerging needs related to knowledge mobilization and informed future improvement opportunities. Throughout the year, dedicated technical maintenance ensured the tool remained reliable, current, and clinically relevant.
Since it’s launch, the tool has continued to demonstrate strong uptake and sustained engagement, amassing over 11,000 active users from Canada, the United States, the United Kingdom, France, Mexico, India, and China, with more than 12,000 direct traffic sessions and over 22,000 user engagement sessions.
Ongoing provincial and national presentations supported continued awareness and use of the tool by promoting shared decision‑making in cholesterol management. These efforts reinforced knowledge mobilization and the tool’s role as an evidence‑based resource for patients and providers, with positive feedback reported across provincial, national, and international audiences.
Co‑designed with patients, clinicians, and health system partners, this digital tool supports shared decision‑making in cholesterol management through accessible, evidence‑based guidance embedded at the point of care, achieving extensive reach and sustained engagement across Canada and internationally.
1 Chen G, Farris MS, Cowling T, et al. Atherosclerotic cardiovascular diseases and low-density lipoprotein cholesterol management in Alberta, Canada [abstract]. Population Science- 91: Epidemiology and Population Studies. presented at: American Heart Association’s Scientific Sessions; November 10-12 2018; Chicago.
2 Butalia, S., Lewin, A., Simpson, S., & others. (2014). Sex-based disparities in cardioprotective medication use in adults with diabetes. Diabetology & Metabolic Syndrome, 6(1), 117. https://doi.org/10.1186/1758-5996-6-117.